Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1677562

This article is part of the Research TopicNanomaterials Mediated Immunomodulation in Cancer: Current Perspective from Bench to ClinicView all 7 articles

Immunodiagnostic Profiling of SPON2 and MSMB as Biomarkers in Prostate Cancer for Nanomaterial-Based Detection Strategies

Provisionally accepted
Jianzeng  YeJianzeng Ye1Fuhua  ZhongFuhua Zhong1Jinquan  XiaJinquan Xia1Jun  ZengJun Zeng2*Zhiye  FangZhiye Fang2
  • 1Shenzhen People's Hospital, Jinan University, Shenzhen, China
  • 2Shenzhen Guangming District People's Hospital, Shenzhen, China

The final, formatted version of the article will be published soon.

Background: This study aimed to validate secreted biomarkers SPON2 and MSMB with tumor-specific expression and immunogenicity for nanomaterial-based prostate cancer diagnostics. Methods: Gene expression data (GSE55945), comprising 13 prostate tumor and 8 normal tissue samples, retrieved from the GEO database and analyzed by Affymetrix Human Genome U133 Plus 2.0 Array platform. Differentially expressed genes (DEGs) were identified using thresholds of |log₂ fold change| >1 and adjusted p< 0.05. Upregulated DEGs filtered for secretory proteins based on annotations from Human Protein Atlas and UniProt databases. Candidate genes were prioritized using receiver operating characteristic (ROC) analysis, selecting those with area under the curve (AUC) > 0.85 for validation. Quantitative reverse transcription PCR (qRT-PCR) was performed using clinical tumor and matched normal prostate tissues, with GAPDH as internal control. Extracellular accessibility and immune relevance of SPON2 and MSMB were evaluated for diagnostic translation. B cell epitope prediction was done using IEDB and VaxiJen tools to assess immunogenic potential. Selected peptide epitopes were synthesized and validated by indirect ELISA using sera from prostate cancer patients and healthy controls. Results: Out of 243 DGE, five upregulated candidates encoding secretory proteins were identified. Of these, SPON2 and MSMB exhibited high diagnostic performance with AUC values of 0.99 and 0.93, respectively. qRT-PCR validation in clinical samples confirmed significant overexpression of SPON2 (~18-fold) and MSMB (~2.6-fold) in prostate tumor tissues compared to matched normal tissues. Both proteins demonstrate extracellular localization and immune accessibility, supporting their feasibility as targets for antibody-or epitope-based capture strategies. These properties position SPON2 and MSMB as ideal candidates for nanoparticle-conjugated peptide biosensors designed for immunomodulated detection of prostate cancer. Epitope E1 (SPON2) and E2 (MSMB) showed antigenicity scores of 0.80 and 0.52, respectively, and were validated by ELISA, with E1 exhibiting significantly higher reactivity in cancer sera (OD 1.49 vs. 0.81, p < 0.01; AUC 0.98) and E2 showing moderate discrimination (OD 1.27 vs. 0.87, p < 0.05; AUC 0.88). Conclusion: SPON2 and MSMB are secretory, immunogenic biomarkers overexpressed in prostate cancer. Their validated B cell epitopes demonstrate strong diagnostic performance, supporting their potential in nanomaterial-based immunodiagnostic strategies for non-invasive prostate cancer detection.

Keywords: prostate cancer, SPON2, MSMB, Immunodiagnostic, secretory biomarkers, nanomaterials, Transcriptomics, Biosensors

Received: 01 Aug 2025; Accepted: 02 Oct 2025.

Copyright: © 2025 Ye, Zhong, Xia, Zeng and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Jun Zeng, cengjun2002@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.